Patents Examined by Shanon A. Foley
  • Patent number: 11357846
    Abstract: The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: June 14, 2022
    Assignee: Valneva SE
    Inventors: Andrea Fritzer, Andreas Meinke, Urban Lundberg, Mario Nebenführ, Jürgen Heindl-Wruss, Robert Schiegl, Arnaud Leon
  • Patent number: 11360088
    Abstract: A method for measuring influenza B virus by an immunoassay, which method enables specific detection of influenza B virus with a higher sensitivity than conventional methods, and a device or a kit therefor are disclosed. The method for measuring influenza B virus includes carrying out an immunoassay of influenza B virus by a sandwich method using two kinds of monoclonal antibodies each of which specifically reacts with the region of the 125th to 248th amino acids of matrix protein (M1) of influenza B virus, which two kinds of monoclonal antibodies are capable of binding to the region of the 125th to 248th amino acids of M1 at the same time, or antigen-binding fragments thereof.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: June 14, 2022
    Assignee: DENKA COMPANY LIMITED
    Inventors: Koichi Inano, Takashi Miyazawa, Osamu Ishikawa
  • Patent number: 11351239
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 7, 2022
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith
  • Patent number: 11351243
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: June 7, 2022
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, David Ewell Slade, Siao-Kun W. Welch
  • Patent number: 11351244
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: June 7, 2022
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith
  • Patent number: 11351241
    Abstract: Immunogenic compositions for inducing a universal immune response to influenza, and particularly influenza A, by eliciting anti-neuraminidase antibodies which provide protection against heterologous influenza infection. Compositions comprising recombinant baculovirus expression vectors expressing neuraminidase in cultured insect cells dispersed in a pharmaceutically-acceptable carrier comprising insect cell culture media, and optional adjuvant. Methods of inducing immune responses against influenza, and particularly influenza A, by eliciting anti-neuraminidase antibodies in a host animal susceptible to infection.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 7, 2022
    Assignee: Cambridge Technologies LLC
    Inventor: Ben Hause
  • Patent number: 11351249
    Abstract: The invention relates generally to vaccine compositions that are capable of eliciting and sustaining an immune response in a subject. The vaccine composition comprises a water-in-oil emulsion and a plurality of immunogen loaded hydrogel particles surrounded with a cationic polymer shell dispersed in the aqueous phase of the emulsion.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: June 7, 2022
    Assignee: CAPSULAR TECHNOLOGIES PTY LTD
    Inventors: David E. Mainwaring, Mohammad Al Kobaisi
  • Patent number: 11352416
    Abstract: The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response. In other embodiments, vectors that recruit and activate specific antigen-presenting cells may further enhance the efficacy of those immune responses.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: June 7, 2022
    Assignee: The TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Waithaka Mwangi, Surya Waghela, Luc Berghman
  • Patent number: 11344617
    Abstract: The present invention describes a liquid vaccine composition of a live enveloped virus and a pharmaceutically acceptable carrier, whereby the carrier is a natural deep-eutectic solvent (NADES), and the vaccine has a water activity of less than about 0.8. The NADES provides a stabilisation of the sensitive virus for prolonged time and at ambient temperature. In general, the liquid vaccine compositions according to the invention, in different compositions for the various enveloped viruses, show remarkable capabilities of stabilisation. This overcomes the need for lyophilisation, a great economic benefit. Also the liquid nature of the vaccines facilitates administration to human or animal targets.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 31, 2022
    Assignee: Intervet Inc.
    Inventors: Paul Vermeij, Edwin Kets, Chris Dirks, Martin Piest
  • Patent number: 11339206
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: May 24, 2022
    Assignee: ADMA BIOMANUFACTURING, LLC
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • Patent number: 11338031
    Abstract: The present invention relates to novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The invention further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: May 24, 2022
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Janneke M. Verhagen
  • Patent number: 11339376
    Abstract: Provided is a host cell for stably propagating a virulent hand, foot and mouth disease virus, the host cell expressing no heparan sulfate and overexpressing primate scavenger receptor class B member 2 (SCARB2). Also provided is a method for screening for an anti-hand, foot and mouth disease virus vaccine or an anti-hand, foot and mouth disease virus drug using a stably cultured virulent hand, foot and mouth disease virus.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: May 24, 2022
    Assignee: Tokyo Metropolitan Institute of Medical Science
    Inventors: Satoshi Koike, Kyousuke Kobayashi, Yui Sudaka, Ayumi Imura
  • Patent number: 11331384
    Abstract: This invention relates to methods to determine vaccine candidate strains that can be used to induce broadly cross-reactive immunity against pathogens, related vaccines, and related methods.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: May 17, 2022
    Assignee: University of Rochester
    Inventor: Christopher S. Anderson
  • Patent number: 11332739
    Abstract: The present invention relates to a method for preparing cDNA infectious clones based on the genome of an attenuated Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and uses thereof for preparing efficacious and safety-enhanced vaccines against PRRSV. The invention further comprises an infectious cDNA clone obtainable by such method. The invention further provides an attenuated modified PRRSV, and immunogenic compositions and vaccines comprising that attenuated PRRSV. The present invention further provides the attenuated PRRSV for use in the prophylaxis and/or the treatment of PRRSV infections, and the attenuated PRRSV for use as vaccine or medicament in the prophylaxis and/or the treatment of PRRSV infections.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: May 17, 2022
    Assignees: HIPRA SCIENTIFIC, S.L.U., CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: Xavier Gibert Pérez, Marta Sitjà Arnau, Maria Mar Fenech Martínez, Santiago Francisco Elena Fito, Susana Martín García
  • Patent number: 11332720
    Abstract: The present disclosure relates to a novel murine parvovirus, sequences encoded thereby, and applications therefor. In one embodiment the disclosure provides a method for detecting the presence of a parvovirus in a sample, comprising detecting one or more nucleic acids or polypeptides derived from the parvovirus, or antibodies against the parvovirus, in the sample. Also provided are vectors and host cells comprising sequences encoded by the parvovirus and related sequences. Also provided are animal models of kidney disease associated with infection by the parvovirus.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 17, 2022
    Assignees: Centenary Institute of Cancer Medicine and Cell Biology, University of Sydney
    Inventors: Ben Roediger, Wolfgang Weninger, Shweta Tikoo
  • Patent number: 11332517
    Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: May 17, 2022
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Yee-Peng Chan, Christopher C. Broder
  • Patent number: 11324816
    Abstract: Described herein are virus-like particles (VLPs) that display on their surfaces antigenic paramyxovirus (e.g., RSV and/or MPV) proteins. Also described are methods of making and using these VLPs.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: May 10, 2022
    Assignee: TechnoVax, Inc.
    Inventors: Jose M. Galarza, Velasco Cimica, Hélène Boigard
  • Patent number: 11312761
    Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: April 26, 2022
    Assignee: Adimab, LLC
    Inventor: Laura M. Walker
  • Patent number: 11305006
    Abstract: The disclosure relates to the technical field of veterinary biological products, and discloses an avian influenza and fowl adenovirus type 4 bi-combined genetic engineering subunit vaccine. An antigen in the vaccine is a fusion antigen; the fusion antigen has a) avian influenza virus HA protein; b) fowl adenovirus fiber2 protein; c) a specific linker peptide located between the avian influenza virus HA protein and the fowl adenovirus fiber2 protein; the amino acid sequence of the specific linker peptide is as shown in SEQ ID NO:2. This vaccine contains the fusion antigen which can induce poultries to produce a high-level specific antibody to protect poultries from avian influenza and fowl adenovirus infection. Meanwhile, the disclosure also discloses a method for preparing the vaccine.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: April 19, 2022
    Assignees: ZHAOQING DAHUANONG BIOLOGY MEDICINE CO., LTD, ZHAOQING INSTITUTE OF BIOTECHNOLOGY CO., LTD
    Inventors: Ruiai Chen, Yanpeng Li, Lianghai Wen, Wenyan Zhang, Jianjun Sun
  • Patent number: 11291715
    Abstract: The present invention relates to the use of a diluent for the in-use stabilisation of cells infected with a cell-associated alphaherpesvirus. Contrary to the long-standing practice of incorporating a considerable amount of peptone into the diluent for such virus-infected cells, it was found that a reduction of the amount of protein in the diluent improved the in-use stability of alphaherpesvirus-infected cells. Whereby the best stability was even obtained using a protein-free diluent. This effect was especially pronounced for recombinant HVT viruses expressing a heterologous insert. Being protein-free is highly advantageous for the production of the diluent, in respect of costs, safety, and consistency of production.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: April 5, 2022
    Assignee: Intervet Inc.
    Inventors: Ad De Groof, Iwan Verstegen